Prevalence of invasive cytomegalovirus disease with administration of muromonab CD-3 in patients undergoing orthotopic liver transplantation.
OBJECTIVE
To assess the association of cytomegalovirus (CMV) disease with the administration of muromonab CD-3 (OKT-3) in patients undergoing liver transplant; specifically, to assess the risk of OKT-3 use as an agent for rejection prophylaxis and as an agent for therapy of rejection.


METHODS
Retrospective review of medical records.


METHODS
83 liver transplant recipients (43 men, 40 women) with a mean age of 41.5 years (range 16-62).


METHODS
The medical record for each liver transplant recipient was reviewed and analyzed for the following variables: (1) preoperative recipient CMV serology, (2) donor CMV serology, (3) incidence of invasive CMV disease, (4) administration of OKT-3, (5) postoperative administration time of OKT-3, and (6) the relationship between the administration of OKT-3 and the prevalence of invasive CMV disease.


RESULTS
OKT-3 was administered to 34 of 83 (40.9 percent) liver remainder received OKT-3 as rejection rescue. All patients received OKT-3 5 mg iv for 14 days. Seventeen of the 34 patients receiving OKT-3 (50 percent) developed invasive CMV disease; 58.8 percent of the patients (20/34) receiving OKT-3 were given the agent within the first 14 postoperative days. Sixteen of these 20 patients (80 percent) developed invasive CMV disease. One of 14 patients (7.1 percent) who received OKT-3 after the first 14 postoperative days developed invasive CMV disease. Of those patients 94 percent (16/17) received OKT-3 in the first 14 postoperative days. This prevalence differed significantly from those receiving OKT-3 after the 14th postoperative day and those who did not receive OKT-3 at any time during their hospital course.


CONCLUSIONS
The patients who received early administration of OKT-3 in our study had a greater risk of invasive CMV disease than did those who received OKT-3 later in the hospital course.
Hooks
M A
MA
Department of Surgery, Emory University School of Medicine, Atlanta, GA.
Perlino
C A
CA
Henderson
J M
JM
Millikan
W J
WJ
Kutner
M H
MH
D000293:Adolescent; D000328:Adult; D003586:Cytomegalovirus Infections / Q000453:epidemiology / Q000209:etiology*; D005260:Female; D005845:Georgia / Q000453:epidemiology; D006084:Graft Rejection / Q000187:drug effects; D006801:Humans; D007108:Immune Tolerance; D016031:Liver Transplantation / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D016853:Muromonab-CD3 / Q000008:administration & dosage / Q000009:adverse effects*; D015995:Prevalence; D012189:Retrospective Studies; D012307:Risk Factors
D016853:Muromonab-CD3